. On the other hand, tumour cells can modulate the expression of surface molecules: (i) to avoid recognition by CTL (e.g. by down-regulating Class I MHC molecules) [16] ; (ii) to impair the binding of lytic granules on their surface [17] ; (iii) to counter-attack CTL aggression (e.g. by expressing FasL on their surface) [18] . Regulatory CD4 ϩ CD25 ϩ cells are also enriched in tumour infiltrates and can further contribute to inhibit CTL effector function [19] .
Additional mechanisms of resistance include intra-cellular effectors that in tumour cells 'defuse' the lytic potential of CTL.
Among these, granzyme inhibitors of the serpin family have been thoroughly characterized [20] .
The above findings indicate that failure of CTL-mediated tumour elimination mainly depends on the difficulty to generate effector cells and to have these cells appropriately activated in the tumour microenvironment. Accordingly, the lytic function of ex vivo isolated CD8
ϩ cells from tumour-infiltrating lymphocytes (TIL) is impaired in human and mouse [21, 22] ; furthermore, freshly isolated CD8 ϩ TIL exhibit defects in adhesion and in proximal TCR signalling [23, 24] .
An additional cause for CTL failure may rely in defective cognate interaction with tumour cells. Surprisingly, although CTL/target cell interaction has been thoroughly investigated both in vitro and in vivo, most of the information available on human CTL biology comes from studies using conventional target cells, such as Epstein-Barr virus (EBV)-transformed B cells and myelomonocytic cell lines. We therefore miss a detailed description of the different steps of CTL/tumour cell interaction that would be instrumental to better define at which level(s) CTL function is defective. We have examined cytotoxicity exerted by CMV-specific or Melan-A/MART-1-specific CTL conjugated with HLA-A2 ϩ cells derived from solid tumours or with conventional targets pulsed with antigenic peptide. Our results show that CTL underwent comparable activation and efficiently polarized their lytic machinery towards target cells when conjugated with melanomas or conventional targets, yet tumour cells were resistant to CTL-mediated cytotoxicity. Timelapse microscopy experiments demonstrated that melanoma cells endure lytic granule delivery for a prolonged time before undergoing apoptosis. The observed 'delayed' lysis of tumour cells may constitute a mechanism to reduce CTL efficiency in controlling the growth of solid tumours in vivo.

Materials and methods
T cells and APC
The HLA-A2-restricted T cell line (CMVpp65) specific for the human cytomegalovirus protein pp65 peptide NLVPMVATV [6] and the [25] T cells were generated and maintained as described [5, 6] . Target cells were cultured in complete RPMI 1640 supplemented with 10% FCS. Microscopy was preformed as previously described [6] . CTL/target cell conjugates were co-cultured for 15 min. [6] .
HLA-A2-restricted T cell clone IFN-DC#1 specific for the Melan-A/MART-1 peptide ELAGIGILTV
FACS analysis and confocal microscopy
Cytotoxic assay
Statistical analysis
Unpaired Student's t-test using the GraphPad Prism software was used to determine the statistical significance of differences between the groups.
Results
Melanoma cells efficiently activate viral-specific CTL
We have previously shown that when interacting with peptidepulsed target cells human CTL specific for the immunodominant epitope of the CMV pp65 protein exhibit a low-threshold cytotoxicity and can kill multiple targets simultaneously [5, 6] .
In activated to lytic granule release by conventional or melanoma cells (Fig. 1B) . Furthermore, JY and melanoma cells induced similar levels of TCR down-regulation and IFN-␥ production in CTL (Fig. S2) (Fig. S6) .
A2 expression on D10 cells before (D10) and after 48 hrs of treatment with 1000 U/ml IFN-␥ (D10 IFN-␥). Lower panels show the frequency D10 cells either unpulsed (U), untreated and pulsed with 10 M peptide (P), or pre-treated for 2 days with IFN-␥ and pulsed with 10 M peptide (P (IFN-␥)) that incorporated PI after 4 hrs of conjugation with CTL. This is a representative result of two independent experiments performed in duplicates. Numbers indicate the frequency of PI-positive cells.
DNA breaks after interaction with CTL when compared to conventional targets. This limited induction of apoptosis was not due to defective caspase-3 expression by melanoma cells
These results indicate that although melanoma cells fully trigger CTL effector function, the tumour cell apoptotic pathway is defectively activated. [28, 29] , we asked whether the efficiency of melanoma cell killing could be improved by increasing the CTL/target cell ratio. Figure 3A 
Melanoma cell annihilation requires a high effector/target cell ratio and is time-dependent
All together the above observations highlight an intriguing resistance of melanoma cells to cytotoxicity mediated by CTL they have efficiently activated. These in vitro results were obtained using a relatively low E/T ratio (2:1). Because melanoma cells were shown to be killed by tumour-specific CTL in previous studies at high E/T ratios
shows that increasing the E/T ratio to 8:1 significantly enhanced cytotoxicity of D10 melanoma cells. We then asked whether the efficiency of melanoma cell killing could be improved by increasing the duration of CTL/target cell interaction. A prolonged interaction with CTL resulted in increased killing of HBL cells, but had poor effect on D10 cell lysis (Fig. 3B). This observation indicates that, provided more time, CTL may succeed to kill part of the tumour cells, even at low E:T ratio. Thus, melanoma cells are not intrinsically resistant to CTL cytotoxicity, because increasing the E/T ratio or prolonging the time of cognate interaction may partially revert the melanoma cell resistance to CTL-mediated attack.
Individual melanoma cells receive and endure CTL hits for a prolonged time
Overall, we find that when individual CTL are stimulated by either conventional or melanoma cells, they get similarly activated. Yet, (Fig. 4C) . On the contrary, the majority of CTL interacting with pulsed JY (Fig. 4B ) and HBL cells (Fig. 4D (Fig. S7) .
We also visualized lethal hit delivery in living CTL/target cell conjugates by time-lapse microscopy. As shown in Fig. S8 [Ca 2ϩ ]i rapidly increases in target cells receiving lytic granules [5, 8, 26] .
Target 
of JY cells (Movie S7 shows an example of resistant HBL cells). On the fraction of cells that died in both populations, we monitored the time required to undergo apoptosis after initial contact with CTL by measuring the time required to detect target cell blebs leading to cell annihilation. Thirty-two CTL/JY conjugates and 31 CTL/HBL conjugates (from at least 8 different movies) were scored. We determined that among susceptible targets, melanoma cells required longer time to be killed (Fig. S9 and Movies S8 and S9). To have a direct visualization of HBL prolonged resistance to CTL attack, we used time-lapse microscopy to monitor CTL interacting simultaneously with peptide-pulsed JY and HBL targets. As shown in Movie S10, the time required for killing melanoma cells largely exceeded the time required to annihilate conventional targets. In fact, whereas JY cells rapidly died upon interaction with CTL, none of the HBL cells died during the time of recording. Together these results indicate that although CMV-specific CTL rapidly secrete and deliver lytic granules to peptide-pulsed melanoma cells, on a cell per cell basis CTL are neither rapid nor efficient in killing melanoma cells.
Melanoma cells are resistant to Melan-A/MART-1-specific CTL
The anti-viral CTL used throughout our study may not adequately mimic anti-tumour CTL since fundamental differences in TCR affinity/ T cell avidity have been described [30] . We therefore extended our analysis to Melan-A/MART-1-specific CTL. Fig. 6B [12, 33] . These observations together with the description of several mechanisms of tumour cell resistance to CTL-mediated cytotoxicity in vitro [22, [34] [35] [36] [2, 3, 5, 6] [28, 29] .
We first assessed whether melanoma cells would adequately activate CTL degranulation. Indeed, at high antigen concentration (10 M) CTL exhibited similar extent of Lamp-1 exposure when conjugated with melanoma or JY cells (Fig. 6A). Interestingly, when target cells were either unpulsed or pulsed with a low concentration of antigenic peptide (1 nM), Lamp-1 exposure was more pronounced in CTL interacting with melanoma cells (Fig. 6A). This observation suggests that the endogenously expressed Melan-A/MART-1 antigen on melanoma cells is sufficient to trigger CTL degranulation. To further characterize Melan-A/MART-1-specific CTL activation, we measured TCR down-regulation in CTL interacting either with melanoma or JY cells. As shown in
Discussion
Several lines of evidence indicate that the immune system plays a fundamental role in limiting tumour development and progression. Experimental tumours develop more frequently in immune suppressed animal models [31] and in human beings with congenital or acquired immune deficiencies [32]. However, although a relatively high frequency of CTL directed against various tumour antigens in cancer patients has been described, the potency of these naturally occurring anti-tumour CTL responses in vivo is poor. Moreover, therapeutic interventions aiming to specifically enhance these responses have thus far provided unsatisfactory clinical benefits
CTL/target cell interaction cytotoxicity was augmented. Moreover, cytotoxicity was also enhanced when E/T target ratio was increased, in agreement with previous reports
Together these observations indicate that tumour cell annihilation is a cumulative process enhanced either by increasing the number of killers or the time given to each individual CTL to deliver multiple hits to the same tumour target. They also suggest that the known capacity of CTL to secrete quanta of lytic granules towards individual target cells to rapidly annihilate them while sparing lytic potential for further encounters [5, 9] [39, 40] , was observed in melanomas as compared to JY cells (Fig. S10) 
expressed in melanomas and JY cells (data not shown). In addition, no increased expression of PI-9, a serine protease inhibitor that inactivates granzyme B [20] and of x-linked inhibitor of apoptosis protein (XIAP) known to be over-expressed in some tumours
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